Gut Microbial Disruption in Critically Ill Patients with COVID-19-Associated Pulmonary Aspergillosis

被引:0
|
作者
Maurer, H. Carlo [1 ]
Schult, David [1 ]
Koyumdzhieva, Plamena [1 ]
Reitmeier, Sandra [2 ,3 ]
Middelhoff, Moritz [1 ]
Rasch, Sebastian [1 ]
List, Markus [4 ]
Janssen, Klaus-Peter [5 ]
Steiger, Katja [6 ]
Protzer, Ulrike [7 ,8 ]
Schmid, Roland M. [1 ]
Neuhaus, Klaus [2 ]
Haller, Dirk [2 ,3 ]
Quante, Michael [1 ,9 ]
Lahmer, Tobias [1 ]
机构
[1] Tech Univ Munich, Sch Med, Dept Internal Med 2, Klinikum Rechts Isar, D-81675 Munich, Germany
[2] Tech Univ Munich, ZIEL Inst Food & Hlth, Sch Life Sci, D-85354 Freising Weihenstephan, Germany
[3] Tech Univ Munich, Chair Nutr & Immunol, Sch Life Sci, D-85354 Freising Weihenstephan, Germany
[4] Tech Univ Munich, Chair Expt Bioinformat, Sch Life Sci, D-85354 Freising Weihenstephan, Germany
[5] Tech Univ Munich, Sch Med, Dept Surg, Klinikum Rechts Isar, D-81675 Munich, Germany
[6] Tech Univ Munich, Inst Pathol, Sch Med, D-81675 Munich, Germany
[7] Tech Univ Munich, Inst Virol, Sch Med, D-81675 Munich, Germany
[8] Tech Univ Munich, Helmholtz Zentrum Munich, D-81675 Munich, Germany
[9] Univ Hosp Freiburg, Sch Med, Dept Internal Med 2, D-79106 Freiburg, Germany
关键词
COVID-19; aspergillosis; CAPA; microbiome; gut; IMMUNITY;
D O I
10.3390/jof8121265
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objectives: COVID-19 disease can be exacerbated by Aspergillus superinfection (CAPA). However, the causes of CAPA are not yet fully understood. Recently, alterations in the gut microbiome have been associated with a more complicated and severe disease course in COVID-19 patients, most likely due to immunological mechanisms. The aim of this study was to investigate a potential association between severe CAPA and alterations in the gut and bronchial microbial composition. Methods: We performed 16S rRNA gene amplicon sequencing of stool and bronchial samples from a total of 16 COVID-19 patients with CAPA and 26 patients without CAPA. All patients were admitted to the intensive care unit. Results were carefully tested for potentially confounding influences on the microbiome during hospitalization. Results: We found that late in COVID-19 disease, CAPA patients exhibited a trend towards reduced gut microbial diversity. Furthermore, late-stage patients with CAPA superinfection exhibited an increased abundance of Staphylococcus epidermidis in the gut which was not found in late non-CAPA cases or early in the disease. The analysis of bronchial samples did not yield significant results. Conclusions: This is the first study showing that alterations in the gut microbiome accompany severe CAPA and possibly influence the host's immunological response. In particular, an increase in Staphylococcus epidermidis in the intestine could be of importance.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Is COVID-19 a risk factor for invasive pulmonary aspergillosis in critically ill patients?
    Berrin, E. R.
    Gorkem, Ahmet E. R.
    Metan, Gokhan
    Halacli, Burcin
    Ersoy, Ebru Ortac
    Hazirolan, Gulsen
    Alp, Alpaslan
    Saribas, Zeynep
    Akdagli, Sevtap Arikan
    Topeli, Arzu
    Uzun, Omrum
    [J]. TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2021, 69 (01): : 118 - 120
  • [42] Renal aspergillosis after COVID-19-associated pulmonary aspergillosis: A case report
    Ghasemian, Roya
    Vahedi Larijani, Lale
    Rasouli, Kimia
    Hedayati, Mohammad Taghi
    Tavakol, Chanour
    Heydari, Keyvan
    Zalpoor, Hamidreza
    Hoseini, Aref
    [J]. CLINICAL CASE REPORTS, 2023, 11 (09):
  • [43] Two cases of COVID-19-associated pulmonary aspergillosis (CAPA)
    Lim, Jin Lee
    Khor, Inn Shih
    Moh, Cheng Keat
    Chan, Yi Min
    Lam, Yoke Fong
    Lachmanan, Kumaresh Raj
    [J]. RESPIROLOGY CASE REPORTS, 2022, 10 (04):
  • [44] Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis reply
    Koehler, Philipp
    White, P. Lewis
    Verweij, Paul E.
    Cornely, Oliver A.
    [J]. LANCET INFECTIOUS DISEASES, 2021, 21 (06): : 767 - 769
  • [45] A fatal case of COVID-19-associated invasive pulmonary aspergillosis
    Iwanaga, Yuto
    Kawanami, Toshinori
    Yamasaki, Kei
    Sakakibara, Hideki
    Ikushima, Issei
    Ikegami, Hiroaki
    Tahara, Masahiro
    Akata, Kentaro
    Mukae, Hiroshi
    Yatera, Kazuhiro
    [J]. JOURNAL OF INFECTION AND CHEMOTHERAPY, 2021, 27 (07) : 1102 - 1107
  • [46] COVID-19-Associated Pulmonary Aspergillosis in the Critical Care Setting
    Livermore, Jennifer M.
    [J]. AACN ADVANCED CRITICAL CARE, 2021, 32 (04) : 398 - 403
  • [47] COVID-19-associated pulmonary aspergillosis: adding insult to injury
    Bruno, Giuseppe
    Fabrizio, Claudia
    Buccoliero, Giovanni Battista
    [J]. LANCET MICROBE, 2020, 1 (03): : E106 - E106
  • [48] Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin
    Costantini, Claudio
    van de Veerdonk, Frank L.
    Romani, Luigina
    [J]. VACCINES, 2020, 8 (04) : 1 - 9
  • [49] COVID-19-associated pulmonary aspergillosis: an underdiagnosed or overtreated infection?
    Rouze, Anahita
    Martin-Loeches, Ignacio
    Nseir, Saad
    [J]. CURRENT OPINION IN CRITICAL CARE, 2022, 28 (05) : 470 - 479
  • [50] A Mexican case series of COVID-19-associated pulmonary aspergillosis
    Perales-Martinez, Diana
    Ruiz-Quinones, Jesus
    de Jesus Barrientos-Flores, Corazon
    Aguilar-zapata, Daniel
    [J]. MEDICAL MYCOLOGY, 2022, 60 (SUPP 1): : 102 - 102